KELI Therapeutics is a clinical-stage biotech university spin-out company specializing in cell-based therapeutics. 💼 Seeking Visionary Investors: We are currently raising 5 Mio EUR (24 months of the runway) to accelerate our lead program, KELI-101, in a First-In-Human, multi-center, adaptive Ph1/2A-B clinical trial (24 months) 🌱 Pioneering Allogeneic GMP-grade Placental Stem Cells: Backed by non-dilutive funding, our proprietary platform has undergone rigorous validation in four non-clinical animal studies, setting new benchmarks for therapeutic potential. 🧪 Expert Team of Biotech Innovators: Our interdisciplinary team boasts top-tier drug developers, regulatory experts, biotechnologists, and physicians, united in delivering groundbreaking medical breakthroughs. 💡 Scalable Manufacturing Excellence: Our placental stromal cell-based 2D/3D manufacturing platform ensures streamlined production of an extensive pipeline of advanced therapeutic medicinal products. ⚙️ Quality Control at the Core: Focusing on rigorous quality control measures, we underscore the safety and efficacy of our innovative therapeutic solutions. 💼 Collaborate for Success: Seeking partnerships with like-minded investors and biotech pioneers to drive healthcare innovation forward. 💰 Investment Opportunities: Join our transformative journey and explore potential significant returns on investment in the rapidly evolving biotech landscape. 🌍 Global Impact, Local Focus: Embrace the future of medicine as we bridge the gap between scientific advancements and patient-centric solutions with a global reach.
